Snack foods and sweet treats have seen a decline in purchases, as people reach for more nutrient-dense options.

Metsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.

With with GLP-1 drugs, gastrointestinal issues, such as nausea, vomiting, constipation, and gastroesophageal reflux disease, ...

By Dr. Priyom Bose, Ph.D. Short-term increase in thyroid cancer diagnoses observed with GLP-1RA initiation, likely driven by ...

The good news is that the risk for thyroid cancer linked to GLP-1 drugs appears low, but higher detections in the first year, ...

A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

If your constipation lasts for more than three days, speak with your doctor about options to help. You might need to add a ...

Patients with metabolic dysfunction-associated steotohepatitis (MASH) who are already taking a glucagon-like peptide-1 ...

Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform ...

Learn more about a new study claiming that GLP-1s could be used to treat cognitive conditions like dementia, but may pose a risk to other vital organs.

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...